Jacobio Pharmaceuticals Group Co., Ltd. (Jacobio Pharma) disclosed a repurchase of 72,300 ordinary shares on 8 May 2026 via the Hong Kong Stock Exchange. Shares were bought at prices ranging from HK$6.29 to HK$6.36, for a volume-weighted average repurchase price of HK$6.31 per share, bringing the total cash outlay to HK$0.46 million.

Following the transaction: • Issued shares outstanding (excluding treasury shares) fell from 784.997 million to 784.925 million, a 0.009% reduction. • Treasury shares rose from 6.76 million to 6.83 million. • Total issued shares remained unchanged at 791.76 million, as the repurchased stock is being held in treasury.

The buyback forms part of the mandate approved on 10 June 2025, which authorises Jacobio Pharma to repurchase up to 78.87 million shares. Cumulative repurchases under this mandate now stand at 3.81 million shares, equivalent to 0.48% of the company’s issued share count on the mandate date.

In line with Hong Kong listing rules, Jacobio Pharma is subject to a moratorium on issuing new shares or disposing of treasury shares until 7 June 2026.